The chemotherapy drug Taxotere, commonly used for breast cancer treatment, has been linked to severe eye injuries, permanent vision loss, and permanent hair loss.
Taxotere lawsuits are being consolidated in the US District Court for the Eastern District of Louisiana, with claims that the manufacturer, Sanofi-Aventis, did not adequately warn about the potential side effects.
Patients who have experienced vision damage, hair loss, or other related medical issues after using Taxotere may be eligible for financial compensation through a lawsuit.
Active Litigation
Taxotere Lawsuit Facts
TorHoerman Law is actively accepting claims for the Taxotere Lawsuit.
Most Recent Updates
150 Taxotere Lawsuits relating to vision loss and eye injuries are centralized in federal court.
Our Taxotere Lawyers are accepting new clients who have suffered vision loss, blurred vision, significant pain, and other visions issues after being prescribed Taxotere.
Contact us today for a free consultation or use the chat feature on this page to find out if you qualify for the Taxotere Lawsuit.
Key Takeaways
The chemotherapy drug Taxotere, commonly used for breast cancer treatment, has been linked to severe eye injuries, permanent vision loss, and permanent hair loss.
Taxotere lawsuits are being consolidated in the US District Court for the Eastern District of Louisiana, with claims that the manufacturer, Sanofi-Aventis, did not adequately warn about the potential side effects.
Patients who have experienced vision damage, hair loss, or other related medical issues after using Taxotere may be eligible for financial compensation through a lawsuit.
Taxotere Lawsuit Update and Overview
The popular chemotherapy drug Taxotere has been linked to severe eye injuries and permanent hair loss.
Taxotere Lawsuits are being filed by breast cancer patients and others who have taken the chemotherapy drug and subsequently developed vision problems such as:
Excessive tearing (epiphora)
Damaged and scarred tear ducts (canalicular stenosis)
Partial vision loss
Permanent vision loss
Severe eye pain
Other eye injuries
Taxotere Lawsuits have also been filed by breast cancer patients who have suffered hair loss due to Taxotere use, but our law firm is focused on seeking justice for Taxotere patients who have suffered from vision loss and other related injuries.
Taxotere Vision Damage Lawsuits are being consolidated into multidistrict litigation (MDL) in the US District Court for the Eastern District of Louisiana.
If you or a loved one used Taxotere and subsequently developed vision damage or other vision problems, you may be eligible to file a Taxotere Lawsuit and seek financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify to file a Taxotere Lawsuit instantly.
Our law firm is committed to helping individuals secure compensation for what they’ve experienced.
Having to undergo cancer treatment is a battle in itself, but having to deal with additional health issues from using a chemotherapy drug can compound the difficulties patients are already dealing with.
Our Taxotere Lawyers are here to help you through this.
Reach out to us for a free consultation or use the chatbot on this page for an instant case evaluation.
Plaintiffs in MDL No. 3023 allege that Taxotere and other docetaxel products caused injuries to the lacrimal system, including narrowing or scarring of the tear ducts that can result in excessive tearing, known as epiphora.
Earlier this year, Judge Jane Triche Milazzo allowed key plaintiffs’ general causation testimony and denied Sanofi’s motion for summary judgment on causation.
Sanofi has also been permitted to pursue an interlocutory appeal involving federal preemption as the remaining eye injury claims continue toward further pretrial proceedings.
The modest decline continues the gradual wind-down of the litigation as remaining claims are resolved, dismissed, or otherwise removed from the federal proceedings.
With new filings largely over, the Taxotere docket continues to shrink as the court works through the remaining cases.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
September 22nd, 2026: MDL Judge Issues Scheduling Order for Bellwether Taxotere Eye Injury Actions
The judge overseeing the federal Taxotere eye injury MDL has issued a scheduling order governing the second wave of bellwether cases against Sanofi.
The September 8th order sets phase one deposition discovery to begin November 2 and close February 1st, 2027.
Rulings on summary judgment motions are expected by May 17th, 2027, ahead of the first trial in this bellwether group, scheduled for October 2027.
Plaintiffs allege Taxotere’s label inadequately warned that the breast cancer chemotherapy drug could cause permanent damage to the lacrimal system, the ducts responsible for draining tears from the eyes.
As scarring progresses, it can permanently narrow these ducts, leading to chronic, irreversible watery eyes and vision problems that sometimes require surgery to correct.
The case is being overseen by Judge Jane Triche Milazzo in the U.S. District Court for the Eastern District of Louisiana, where the eye injury claims are consolidated as MDL 3023, separate from an earlier Taxotere hair loss MDL.
This scheduling order follows a December 2025 ruling in which Milazzo denied Sanofi’s motion for summary judgment, allowing the eye injury claims to continue moving toward trial.
No global settlement has been reached in either the hair loss or eye injury litigation.
The modest decline comes as the Taxotere eye injury litigation continues through bellwether proceedings and case-specific motions following a series of important rulings on preemption, expert testimony, and causation.
Although the docket has contracted substantially, the remaining claims continue to move toward potential trials over allegations that Taxotere caused permanent damage to the lacrimal system and that Sanofi failed to adequately warn patients and physicians about the risk.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
The litigation remains in its final stages after years of bellwether trials, appellate rulings, and settlements, with most remaining cases focused on individual resolution rather than broad pretrial issues.
The steady decline reflects the continued wind-down of one of the longest-running pharmaceutical MDLs in the federal court system.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
July 13th, 2026: Judge Allows Taxotere Watery Eyes Lawsuits to Proceed to Trial
A federal judge has denied Sanofi’s motion for summary judgment in the Taxotere watery eyes MDL, allowing claims that the company failed to adequately warn about the risk of chronic watery eyes and tear duct injuries to proceed.
In a June 25 order, U.S. District Judge Triche Milazzo found that factual disputes remain over whether Taxotere’s warning label sufficiently described the nature and severity of the risk, and ruled that those questions should be decided by a jury.
The ruling keeps the litigation on track for future bellwether trials, where representative cases will test how juries respond to evidence and expert testimony.
Judge Milazzo rejected Sanofi’s argument that the warnings were adequate as a matter of law, writing that there are significant disputes over whether the label was misleading and whether it properly conveyed the risks associated with Taxotere.
The slight reduction reflects the mature stage of the litigation, where case resolutions and dismissals continue to outpace new filings.
With most major bellwether and appellate issues already addressed, the remaining Taxotere lawsuits are focused on individual case resolution and final pretrial proceedings.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
The decline reflects ongoing case resolutions and dismissals as the docket winds down.
The court continues to manage remaining claims in late-stage proceedings, with no new JPML transfer activity reported during the month.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
April 1st, 2026: April 2026 JPML Update
The Taxotere lawsuit recorded a decrease in total multidistrict litigation (MDL) cases from March 2026 to April 2026.
The docket declined from 375 total cases in March 2026 to 159 total cases in April 2026, a net reduction of 216 cases, which likely indicates dismissals, settlements, or other case resolutions.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
March 3rd, 2026: Fifth Circuit To Review Preemption Issue In Taxotere Lawsuit MDL Over Eye Injury Warnings
A federal judge has granted pharmaceutical manufacturer Sanofi permission to pursue an interlocutory appeal in the ongoing Taxotere Lawsuit MDL, allowing the U.S. Court of Appeals for the Fifth Circuit to examine a key legal question involving federal drug labeling requirements.
The ruling allows the appellate court to determine whether federal drug labeling regulations preempt failure-to-warn claims brought by cancer patients.
Taxotere is the brand name for docetaxel, a chemotherapy drug manufactured by Sanofi and commonly prescribed to treat breast cancer.
Cancer patients involved in Taxotere Lawsuits allege that the chemotherapy drug caused nasolacrimal duct stenosis, a medical condition involving narrowing or blockage of tear drainage ducts.
The condition can lead to chronic tearing, eye irritation, and surgical intervention.
Plaintiffs in Taxotere Lawsuits claim the drug’s labeling failed to warn that the condition could become permanent.
The multidistrict litigation (MDL) currently consolidates multiple Taxotere Lawsuits filed across the United States.
Multidistrict litigation is a federal legal procedure designed to centralize lawsuits that involve similar factual allegations.
The Judicial Panel on Multidistrict Litigation consolidates cases before a single federal judge to coordinate discovery and pretrial proceedings.
Sanofi sought dismissal of the claims by arguing that federal law prevents pharmaceutical manufacturers from changing drug safety warnings without approval from the U.S. Food and Drug Administration (FDA).
Sanofi argued that no “newly acquired information” existed that would justify modifying the Taxotere label during the relevant period.
Judge Milazzo rejected that argument in a December ruling.
The court determined that at least one scientific publication, the 2003 Esmaeli Cancer Study, suggested docetaxel treatment could cause narrowing of tear ducts and related eye injuries.
The court stated that the Taxotere label was last updated in 2002 and remained unchanged for approximately 18 years despite emerging research.
Sanofi also argued that a January order dismissing claims against generic manufacturers Accord Healthcare Inc. and Sandoz Inc. created inconsistent legal conclusions.
The court determined that generic manufacturers operate under different regulatory requirements because generic drug labels must match the brand-name drug label approved by the FDA.
The docket remains largely stable as remaining claims proceed through late-stage pretrial management.
No new JPML transfer activity or significant court rulings were reported during the month.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
February 18th, 2026: Allegations, MDL Status, and Legal Background of the Taxotere Lawsuit
Taxotere lawsuits involve claims that the chemotherapy drug Taxotere (docetaxel) caused serious eye injuries and permanent vision loss in breast cancer patients without adequate warning.
Plaintiffs in Taxotere Lawsuits allege that the drug can cause severe ocular complications, including cystoid macular edema, optic neuropathy, excessive tearing, and other vision-related injuries that may result in partial or permanent vision impairment.
The claims assert that Sanofi failed to adequately warn patients and physicians about the risk of serious eye damage associated with Taxotere use.
Plaintiffs further allege that the manufacturer promoted Taxotere as an effective chemotherapy option without fully disclosing the potential for significant and lasting vision complications.
Unlike temporary side effects that may resolve after chemotherapy ends, plaintiffs allege that certain Taxotere-related eye injuries can persist long after treatment is completed. Vision loss and chronic eye conditions may interfere with daily activities, employment, and overall quality of life during and after cancer recovery.
The Judicial Panel on Multidistrict Litigation consolidated federal Taxotere Lawsuits into a multidistrict litigation (MDL).
Multidistrict litigation is a federal procedure that centralizes similar cases before one judge to coordinate pretrial proceedings, including discovery and expert testimony.
Centralization allows courts to manage large volumes of product liability claims efficiently while preserving each plaintiff’s individual case for trial or settlement.
February 18th, 2026: Allegations, MDL Status, and Legal Background of the Taxotere Lawsuit
Taxotere lawsuits involve claims that the chemotherapy drug Taxotere (docetaxel) caused serious eye injuries and permanent vision loss in breast cancer patients without adequate warning.
Plaintiffs in Taxotere Lawsuits allege that the drug can cause severe ocular complications, including cystoid macular edema, optic neuropathy, excessive tearing, and other vision-related injuries that may result in partial or permanent vision impairment.
The claims assert that Sanofi failed to adequately warn patients and physicians about the risk of serious eye damage associated with Taxotere use.
Plaintiffs further allege that the manufacturer promoted Taxotere as an effective chemotherapy option without fully disclosing the potential for significant and lasting vision complications.
Unlike temporary side effects that may resolve after chemotherapy ends, plaintiffs allege that certain Taxotere-related eye injuries can persist long after treatment is completed. Vision loss and chronic eye conditions may interfere with daily activities, employment, and overall quality of life during and after cancer recovery.
The Judicial Panel on Multidistrict Litigation consolidated federal Taxotere Lawsuits into a multidistrict litigation (MDL).
Multidistrict litigation is a federal procedure that centralizes similar cases before one judge to coordinate pretrial proceedings, including discovery and expert testimony.
Centralization allows courts to manage large volumes of product liability claims efficiently while preserving each plaintiff’s individual case for trial or settlement.
The docket remains largely static, consistent with a mature MDL nearing the end of coordinated proceedings.
No new JPML actions or significant docket developments were reported during the month.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
January 5th, 2026: Tepezza Lawsuit January JPML Filing Update
The Taxotere lawsuit recorded a decrease in total multidistrict litigation (MDL) cases from December 2025 to January 2026.
The docket declined from 375 total cases in December 2025 to 373 in January 2026, reflecting a net reduction of 2 cases, which typically indicates dismissals or case resolutions rather than new filings.
The Taxotere lawsuit involves claims that the chemotherapy drug Taxotere (docetaxel) caused permanent hair loss in breast cancer patients.
Plaintiffs allege that the drug manufacturer failed to provide adequate warnings about the risk of long-term or irreversible alopecia associated with Taxotere treatment.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
December 2nd, 2025: Tepezza Lawsuit December JPML Filing Update
The Tepezza lawsuit recorded a moderate increase in total multidistrict litigation (MDL) cases from November 2025 to December 2025.
The docket rose from 371 cases in November 2025 to 375 cases in December 2025, resulting in 4 new filings.
The Tepezza lawsuit involves claims that the thyroid eye disease medication Tepezza caused hearing loss or tinnitus.
Plaintiffs allege that the drug’s labelling did not provide sufficient warnings regarding potential auditory side effects, including the risk of permanent or progressive hearing impairment.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
Plaintiffs continue to claim that Sanofi-Aventis failed to properly warn users about the risk of permanent hair loss associated with the chemotherapy drug.
The slight rise in case count reflects ongoing interest in this litigation, though the overall pace of new filings remains stable.
The MDL remains active as both sides prepare for further proceedings.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
The multidistrict litigation (MDL) has progressed slowly, with relatively few new filings each month, but the consistent presence of new claims highlights ongoing awareness and outreach efforts targeting impacted individuals.
The overall volume of cases remains steady as the litigation continues toward resolution.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
Plaintiffs continue to pursue claims that the chemotherapy drug caused permanent hair loss without adequate warning.
The steady filing pace suggests continued interest in pursuing individual claims as the litigation progresses.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
Plaintiffs continue to pursue claims that the chemotherapy drug caused permanent hair loss without adequate warning.
The steady filing pace suggests continued interest in pursuing individual claims as the litigation progresses.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
June 2nd, 2025: June 2025 JPML Update
The Taxotere MDL saw a minimal increase between May and June, with one new case added, bringing the total to 344.
Although growth has slowed, discovery and expert challenges continue as plaintiffs allege that Sanofi failed to adequately warn users of the risk of permanent hair loss.
Earlier court filings highlighted disputes over causation evidence and the admissibility of expert testimony, which may shape how future bellwether trials proceed.
No trial dates are currently scheduled, but attorneys remain engaged in evaluating scientific evidence and coordinating with the court on the next procedural steps.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
May 1st, 2025: The Taxotere Eye Injury Lawsuit is ongoing.
28 cases have been added to the litigation since January 1st.
Though the pace of filings has slowed, the MDL continues to move forward as plaintiffs seek accountability for talc-related injuries.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
April 1st, 2025: April 2025 JPML Update
In April 2025, the Taxotere Lawsuit saw a notable increase in the number of new filings, with 342 cases recorded.
315 cases were reported in March 2025, with the new numbers reported by the JPML on April 1st representing a rise of 27 cases.
This uptick in filings may be attributed to continued public awareness and increased outreach regarding the potential side effects associated with Taxotere use.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
March 3rd, 2025: Taxotere Filings Dip Slightly to 315 Cases in March
In March 2025, the number of new filings in the Taxotere litigation decreased slightly to 315, a drop of 1 case from the 316 filings recorded in February 2025.
February had seen a modest increase of 1 case compared to the previous month.
The small fluctuation in filings reflects a period of stability in the litigation, which continues to address the claims of individuals who allege harm from the chemotherapy drug Taxotere.
Taxotere, a chemotherapy drug, has been linked to severe eye injury and vision loss, leading to ongoing litigation against its manufacturer, Sanofi-Aventis.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
February 3rd, 2025: February 2025 JPML Update
In February 2025, the number of Taxotere Eye Injury Lawsuits increased slightly to 316, an uptick of 1 filing compared to the 315 cases reported in January 2025.
Plaintiffs claim that the drug’s manufacturer failed to adequately warn patients about the potential risks of eye injury, leading to significant and lasting health complications.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
Taxotere, a chemotherapy drug, has been linked to severe eye injury and vision loss, leading to ongoing litigation against its manufacturer, Sanofi-Aventis.
The increase in case filings highlights the continued legal actions taken by individuals who experienced vision loss after using Taxotere as part of their cancer treatment.
Lawsuits often focus on claims that the manufacturer failed to adequately warn patients and healthcare providers about the risk of vision damage associated with the drug.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
December 2nd, 2024: The Taxotere Eye Injury Lawsuit is ongoing.
The Judicial Panel on Multidistrict Litigation (JPML) reported 320 case filings for the Taxotere lawsuit in November.
The Taxotere lawsuit involves claims that the chemotherapy drug Taxotere caused permanent hair loss, a condition not adequately disclosed to patients.
The decrease in filings may be attributed to the litigation reaching a more advanced stage or a decline in new claimants coming forward.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
November 1st, 2024: The Taxotere Eye Injury Lawsuit is ongoing.
The Judicial Panel on Multidistrict Litigation (JPML) reported 312 case filings for the Taxotere lawsuit in October.
By November, the number of case filings increased to 320, reflecting a growth of 8 cases.
The Taxotere lawsuit involves claims that the chemotherapy drug Taxotere caused permanent hair loss, a side effect not adequately disclosed to patients.
The increase in filings may be attributed to continued awareness among cancer survivors and efforts by legal professionals to reach individuals affected by the drug’s alleged side effects.
The Taxotere multidistrict litigation continues to see new developments as more plaintiffs join the legal action against the drug manufacturer.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
October 1st, 2024: October 2024 JPML Update
The Taxotere Eye Injury Lawsuit involves claims against Sanofi regarding the chemotherapy drug Taxotere, with plaintiffs alleging that Taxotere causes severe eye injuries, including excessive tearing and vision problems.
In September, the Judicial Panel on Multidistrict Litigation (JPML) reported 320 active Taxotere lawsuits.
Despite this decrease, the number of active lawsuits continues to reflect concerns over the drug’s side effects and the lack of adequate warnings.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
September 1st, 2024: Taxotere Eye Injury Filings Grow From 308 to 320 Cases
The Taxotere Lawsuit, which claims that the chemotherapy drug Taxotere has caused permanent vision loss and eye injuries in patients, continues to see an increase in filings.
In August 2024, there were 308 active cases in the Taxotere Eye Injury Lawsuit.
Plaintiffs in this lawsuit allege that Sanofi, the manufacturer of Taxotere, failed to adequately warn patients about the risk of vision loss, which has significantly impacted their quality of life.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to instantly find out if you qualify for the Taxotere Eye Injury Lawsuit.
August 1st, 2024: The Taxotere Eye Injury Lawsuit is ongoing.
The Taxotere Eye Injury Lawsuit involves claims against Sanofi regarding the chemotherapy drug Taxotere.
Plaintiffs allege that Taxotere causes severe eye injuries, including excessive tearing and vision problems.
In July, there were 301 filings in the Taxotere Eye Injury lawsuit.
The rise in filings indicates growing awareness and concern about the potential eye-related side effects of Taxotere, leading more individuals to seek legal action.
Taxotere, used in chemotherapy treatment, has been reported to cause eye injuries such as excessive tearing and vision impairment.
These side effects can significantly impact patients’ quality of life, prompting many affected individuals to file lawsuits against Sanofi for failing to provide adequate warnings about these risks.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
July 17th, 2024: Taxotere Lawsuits Center on Tear Duct Damage and Vision Injuries
The Taxotere Eye Injury Lawsuit is ongoing, and our lawyers are still accepting cases from those affected by eye injuries linked to the chemotherapy drug Taxotere.
Taxotere Lawsuits primarily involve claims of excessive tearing, canalicular stenosis, tear duct damage, and other severe eye conditions resulting from the use of the drug.
The core arguments in the Taxotere Eye Injury lawsuits revolve around:
Failure to Warn: Plaintiffs argue that the manufacturers did not provide adequate warnings about the risk of eye injuries associated with Taxotere.
Negligent Design: Allegations include that the formulation of Taxotere contributes to an increased risk of eye injuries, including excessive tearing and canalicular stenosis.
Lack of Adequate Instructions: Lawsuits claim that the manufacturers failed to provide proper instructions on how to mitigate the risk of eye injuries while using Taxotere.
Healthcare professionals recommend the following precautions for those using Taxotere:
Monitor Eye Health: Schedule regular eye exams to detect and address any early signs of eye conditions.
Report Symptoms Promptly: Immediately inform your healthcare provider if you experience excessive tearing, dry eyes, or other eye-related symptoms.
Discuss with Your Doctor: Talk to your healthcare provider about the potential eye risks and ways to mitigate them while undergoing treatment with Taxotere.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
July 1st, 2024: The Taxotere Eye Injury lawsuit is ongoing.
The Taxotere Eye Injury lawsuit involves claims that the chemotherapy drug Taxotere causes significant eye injuries, including excessive tearing and permanent damage.
This lawsuit seeks to hold the manufacturer accountable for these adverse effects.
In June, there were 273 Taxotere Eye Injury lawsuit filings.
Taxotere causes eye injuries by damaging the tear ducts, leading to chronic tearing, infections, and potential vision loss.
These severe impacts have prompted more individuals to join the Taxotere Eye Injury lawsuit.
The Taxotere Eye Injury lawsuit aims to hold the manufacturer responsible for the harm caused by the drug.
Affected individuals should consult a Taxotere Eye Injury lawyer to explore their legal options.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
June 3rd, 2024: The Taxotere Eye Injury Lawsuit is ongoing and our lawyers are actively accepting new cases.
These lawsuits are associated with alleged eye injuries caused by the chemotherapy drug Taxotere.
The claims assert that Sanofi-Aventis, the manufacturer of Taxotere, did not adequately warn patients and healthcare providers of the potential for permanent and severe eye complications, such as Canalicular Stenosis, resulting from the drug’s use.
If you or a loved one suffered eye injury or vision loss after Taxotere use, you may be eligible to join others in filing Taxotere Eye Damage Lawsuits.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Vision Damage Lawsuit instantly.
May 24th, 2024: The Taxotere Eye Injury Lawsuit is ongoing and our lawyers are actively accepting new cases.
Taxotere can cause canalicular stenosis, a condition that leads to excessive eye watering and subsequent vision problems.
This condition occurs when the tear ducts become inflamed and narrowed due to the drug’s side effects, leading to excessive tearing.
The excessive tearing can become chronic and interfere with daily activities, as the tears do not drain normally but instead overflow onto the face.
This persistent wetness can cause irritation, infection, and further complicate vision by blurring and potential damage to the cornea.
Sanofi-Aventis, the manufacturer of Taxotere, faces allegations that it failed to provide adequate warnings to patients and healthcare providers about the risk of severe eye injuries.
Potential settlements in the Taxotere Lawsuit may range between $20,000 to a few hundred thousand dollars per person depending on individual circumstances and the direction of the litigation as a whole.
If you or a loved one suffered eye injury or vision loss after Taxotere use, you may be eligible to join others in filing Taxotere Eye Damage Lawsuits.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Vision Damage Lawsuit instantly.
April 1st, 2024: The Taxotere Eye Injury Lawsuit is ongoing.
According to the latest JPML filings, the number of Taxotere Lawsuits consolidated in the MDL has remained at 268.
No Taxotere Eye Injury cases were added to the MDL in the month of March.
If you or someone you know has been adversely affected by Taxotere, obtaining legal counsel could be an essential step.
For detailed information and to discuss your case, please contact our office for a free consultation.
You can also use the chatbot on this page to find out if you qualify for a Taxotere Eye Injury Lawsuit today.
March 1st, 2024: The Taxotere Eye Injury Lawsuit is ongoing.
A total of 268 Taxotere Eye Injury Lawsuits are pending consolidation as per the latest JPML filings.
On February 1st, the JPML reported 258 Taxotere Eye Injury Lawsuits consolidated into the MDL.
One month later, on March 1st, the JPML indicated that ten cases were added to the litigation and the current number of Taxotere Eye Injury cases in the litigation was 268. Multidistrict Litigations (MDLs) are structured to handle numerous related civil lawsuits that involve similar issues, facts, or defendants.
This legal procedure is adopted when multiple individuals or entities file lawsuits related to a common set of circumstances.
In this case, the circumstances pertain to alleged eye injuries resulting from the chemotherapy drug Taxotere.
Taxotere Eye Injury Lawsuits allege that the manufacturer, Sanofi-Aventis, failed to warn patients and healthcare providers about the risk of developing permanent and severe eye complications, like Canalicular Stenosis, as a result of using Taxotere.
If you or a loved one believe that Taxotere has affected you, we encourage you to reach out to our legal team.
Our experienced attorneys will help you understand your rights and guide you through the legal process. You can also access the chatbot on this page for instant feedback.
February 5th, 2024: The Taxotere Eye Injury Litigation is ongoing and our lawyers are still accepting more cases.
As of February 2024, there are a total of 258 Taxotere Eye Injury Lawsuits pending in the MDL according to the most recent JPML filings.
This MDL is different from the Taxotere Products Liability Litigation which dealt with hair loss due to Tepezza use.
Multi-District Litigations (MDLs) are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.
When numerous individuals or entities file lawsuits related to a common set of circumstances, such as eye injuries resulting from Tepezza, these cases can be consolidated into a single federal district court for pretrial proceedings.
MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.
If you or a loved one were administered Taxotere and subsequently developed vision loss or other eye injuries, you may be eligible to file a Taxotere Lawsuit.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for a Taxotere Lawsuit instantly.
January 12th, 2024: The Taxotere Litigation is ongoing and our lawyers are still accepting new clients.
Currently, there are a total of 258 filings in the Taxotere (Docetaxel) Eye Injury Products Liability Litigation, according to the most recent JPML filings published on January 2nd.
Individuals who have suffered eye injuries subsequent to using Taxotere may be eligible to file a lawsuit and be included in the MDL.
When numerous individuals are impacted by the same product or medication, these cases can be consolidated into a single federal district court for pretrial proceedings, a process called multidistrict litigation (MDL).
MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.
Reach out to our attorneys if you have questions about Taxotere eye injuries or how to get involved in the Taxotere Eye Injury Lawsuit.
If you or a loved one were administered Taxotere and subsequently developed vision loss or other eye injuries, you may be eligible to file a Taxotere Lawsuit.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for a Taxotere Lawsuit instantly.
September 25th, 2023: The Taxotere Lawsuit is ongoing, and our lawyers are accepting new clients.
The pretrial negotiation period is still ongoing, and signs still show that there is a possibility the Taxotere litigation could be settled by the end of the year.
The Taxotere Eye Injury Litigation currently has 240 pending cases and the Taxotere Products Liability Litigation currently has 10,209 cases.
While the Eye Injury Litigation added 7 cases since last month, the Product Liability Litigation saw a reduction of 201 cases.
If you or a loved one were administered Taxotere and subsequently developed vision loss or other eye injuries, you may be eligible to file a Taxotere Lawsuit.
August 8th, 2023: The Taxotere lawsuit is ongoing, and THL lawyers are accepting clients from all 50 states.
Currently, the plaintiffs and defendants are in a pre-trial negotiating period, and there have been some minor developments that indicate this litigation could be settled in 2023.
The plaintiffs and settlement committee (a type of committee created to help victims receive proper settlements) came up with a settlement offer in 2021, but the U.S. Court of Appeals for the First Circuit remanded this offer.
This remand resulted in a delay of any settlements being finalized as well as the plaintiffs having to recreate their settlement approach.
It has now been around two years since the settlement process was restarted, and the fate of the litigation remains one that will either soon settle or go to trial.
If you or a loved one suffered eye injury or vision loss after receiving Taxotere, you may be eligible to file a Taxotere Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify to file a Taxotere Lawsuit instantly.
July 14th, 2023: The Taxotere Eye Injury Lawsuit is ongoing and our Taxotere Lawyers are accepting new clients from all 50 states.
As of July 2023, there have been no settlements made in the Taxotere Lawsuit.
Taxotere Eye Injury Lawsuits are consolidated into multidistrict litigation in the US District Court for the Eastern District of Louisiana.
If you or a loved one suffered eye injury or vision loss after receiving Taxotere, you may be eligible to file a Taxotere Lawsuit and pursue financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify to file a Taxotere Lawsuit instantly.
Sanofi-Aventis first started facing Taxotere Lawsuits over the potentially permanent hair loss side effects of the drug.
Recently, the potential vision loss side effects of Taxotere have triggered the formation of a Taxotere Eye Injury MDL.
Taxotere Hair Loss Lawsuits and Taxotere Vision Damage Lawsuits are consolidated into different multidistrict litigations.
The Taxotere Hair Loss Lawsuits are consolidated into MDL 2740 and Taxotere Vision Damage Lawsuits are consolidated into MDL 3023.
Taxotere Lawsuits claim that Sanofi-Aventis did not adequately warn patients and warn doctors about potential vision loss or permanent hair loss side effects of the drug.
What is Taxotere?
Taxotere is an intravenous chemotherapy drug belonging to the taxanes class.
Taxotere, produced by Sanofi-Aventis, is the brand name for docetaxel.
First introduced in the late 1990s, Taxotere has been used to treat various cancers, including breast, lung, prostate, and stomach cancer.
Taxotere dosing and frequency of administration may vary depending on the specific cancer being treated and an individual patient’s health status.
Taxotere is typically administered in cycles, with each cycle lasting three weeks.
The cycles are repeated until the prescribed number of cycles is completed or until the patient’s oncologist determines that the treatment should be stopped or modified.
Taxotere Lawsuit Settlement Amounts
Taxotere Lawsuits are still ongoing.
Judge Milazzo has yet to issue a ruling, and no settlements have been awarded.
These projections are just estimated settlement amounts based on past settlements in similar dangerous drug claims.
These estimates are by no means a guarantee of financial compensation in the Taxotere Lawsuit.
Contact an experienced attorney for insight on your individual case.
If you need an attorney who advocates for your rights and will fight for the compensation you deserve, look no further.
Contact TorHoerman Law for a free consultation or use the chatbot on this page to find out if you qualify for the Taxotere eye injury lawsuit.
How Many Taxotere Lawsuits Have Been Filed? Current Status of the Taxotere MDL
The Taxotere MDL continues to grow, with over 300 pending Taxotere Lawsuits filed as of January 2025.
New Taxotere Lawsuits are currently being filed by lawyers across the country.
If you or a loved one developed vision loss or other vision issues after taking Taxotere, you may be eligible to file a Taxotere Lawsuit and secure financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Lawsuit instantly.
Taxotere Eye Injury MDL Developments
The Taxotere Eye Injury MDL, centralized in the Eastern District of Louisiana, continues to move forward with active case management and pretrial proceedings.
Plaintiffs, many of whom were administered Taxotere while undergoing chemotherapy, allege that the drug’s manufacturer failed to adequately warn about permanent eye injuries, including canalicular stenosis and chronic tearing.
As with the related hair loss litigation, these cases begin with the filing of Short Form Complaints, and the court has allowed plaintiffs to submit amended short form complaints under the procedures established by various Pretrial Order No. directives.
Discovery and dispositive motions remain critical stages of the litigation.
The court has issued rulings on summary judgment, including summary judgement based on statute-of-limitations defenses, underscoring the importance of timely filing and well-documented medical histories.
The MDL also uses status conferences and meetings with a dedicated settlement committee to evaluate the prospects of resolution, though no global settlement has yet been announced.
Bellwether trials play a pivotal role in testing the strength of both sides’ evidence before broader negotiations.
The MDL has already seen a jury trial in earlier Taxotere hair loss cases and anticipates a second bellwether trial for eye injury claims to further gauge liability and damages.
These outcomes will help shape the trajectory of potential settlements and inform the strategy of attorneys representing affected patients.
The breast cancer chemotherapy drug Taxotere has been associated with a number of vision-related injuries.
Specifically, it is claimed that Taxotere may secrete into the tear ducts and cause severe damage.
The damage of the tear duct system can lead to excessive tearing and pooling of tears in the eyes.
Doctors have been known to misdiagnose patients with excessive tearing symptoms, not knowing that the lacrimal system is scarred and damaged by the drug.
Vision damage injuries related to Taxotere include, but are not limited to:
Lacrimal duct obstruction
Canalicular stenosis
Punctal stenosis
Swollen eyelids
Excessive tearing (Epiphora)
Blocked tear ducts
Cystoid macular edema (vision loss)
Eye irritation
Blurred vision
Eye floaters
Severe eye pain
Other eye injuries
What Medical Treatments Do Eye Injury Patients Need?
If you begin to suffer eye related side effects of Taxotere, seek immediate treatment from a licensed medical professional.
Permanent damage to your vision is possible with Taxotere side effects.
Patients suffering from vision problems and severe eye pain may need to undergo medical treatments.
These medical treatments may include the placement of stents into nasolacrimal system, such as silicone stents or tubes and permanent jones tubes.
The eye injuries associated with docetaxel (Taxotere) for the treatment of breast cancer have been identified in scientific research for at least two decades.
Scientific studies on lacrimal duct obstruction, excessive tearing, and other eye injuries related to Taxotere cases include:
Journal of Clinical Oncology: The incidence and severity of epiphora and canalicular stenosis appears to be higher in patients receiving weekly docetaxel
Liver damage caused by chemical exposure due to Taxotere treatment.
Hepatotoxicity can cause severe complications and even be life-threatening.
Hepatotoxicity is common in patients with:
Abnormal liver function
Elevated LFT
Fluid Retention
Taxotere’s label warns that the condition may reach severe levels for some patients.
Neutropenia
A low neutrophils (specific white blood cell) count makes patients more likely to contract bacterial infections.
If gone untreated, these bacterial infections can cause severe health conditions and even death.
Patients with neutrophil counts under 1500 cells per 3 cubic millimeters of blood volume are more susceptible to develop neutropenia and are advised against using Taxotere unless necessary.
Doctors are advised to frequently check blood counts for these patients who do use Taxotere.
Hypersensitivity Reactions
Reactions like a rash, low blood pressure, and fatal anaphylaxis.
Patients who received dexamethasone premedication are most susceptible to developing these conditions.
There are people filing Taxotere Lawsuits with the help of experienced attorneys in all 50 states.
Our lawyers are investigating the cancer drug Taxotere and helping injured victims seek compensation for what they’ve gone through.
If you or a loved one suffered vision loss or other related health problems from Taxotere, you may be eligible to file a Taxotere Lawsuit.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify to file a Taxotere Lawsuit instantly.
Your Taxotere lawyer will work to build a strong case to prove thatliability for your injuries falls on the manufacturer.
Your Taxotere attorney will work to gather evidence to show liability, assess damages that you incurred from your injuries, file legal documents on your behalf, and work to gain you compensationfor your injuries in the form of a settlement or verdict.
Gathering Evidence for Taxotere Lawsuits
Evidence is extremely important for Taxotere vision damage lawsuits.
Your Taxotere Lawyers will help you gather evidence relevant to your case, but you can begin collecting and retaining evidence on your own.
Evidence for Taxotere Lawsuits may include:
Medical records
Treatment records
Oncology records
Proof that you received Taxotere
Photos and videos of injuries
Any other proof of Taxotere use and subsequent medical problems
Assessing Damages in Taxotere Lawsuits
Damages refer to the total amount of losses related to receiving Taxotere and subsequently developing vision loss or eye injuries.
Your Taxotere Lawyer will help you assess and calculate your damages, using collected evidence to advocate for maximum financial compensation.
Potential damages in a Taxotere Vision Loss Lawsuit may include:
Medical bills
Future medical expenses and medical costs
Pain and suffering
Emotional distress
Lost quality of life
Lost wages and earning ability
Permanent damage to vision resulting in disability
TorHoerman Law’s team of attorneys and legal support staff are experienced in products liability litigation and have a track record of securing compensation for people harmed at no fault of their own.
We understand how difficult it can be to pursue legal action as you’re dealing with breast cancer treatment and side effects of defective drugs.
Our team is here to fight on your behalf and protect your best interests as you focus on your health.
We operate on a contingency fee basis, so our clients do not ever pay any legal fees until after they have been awarded compensation.
No compensation? No fees.
If you or a loved one developed vision loss or other vision issues after taking Taxotere, you may be eligible to file a Taxotere Lawsuit and secure financial compensation.
Contact TorHoerman Law for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Lawsuit instantly.
Across all litigations, TorHoerman Law has secured over $4 billion in negotiated settlements and verdicts.
We aren’t afraid to take on large and influential corporations that injure innocent people.
Reach out to us for more information and speak with our team today.
Taxotere (active ingredient: docetaxel) is manufactured by Sanofi-Aventis and was first approved by the U.S. Food and Drug Administration in May 1996.
Taxotere is used to treat an array of cancers but is most commonly prescribed to treat patients with locally advanced or metastatic breast cancer, which had progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy.
The drug is also used as an adjuvant treatment in combination with doxorubicin and cyclophosphamide for individuals with operable node-positive breast cancer.
Taxotere works in stopping the spread of cancerous cells by cutting off the dividing and multiplying of cells in and around a cancerous clump.
Taxotere falls under a specific class of chemotherapy treatments called taxane drugs – made from plant alkaloids.
Of the drugs used to treat breast cancer, Taxotere is the most prescribed drug in its class (taxane) – some sources estimate that 75% of breast cancer patients will receive Taxotere as a form of treatment.
TorHoerman Law is accepting lawsuits for people who have experienced vision damage or permanent vision loss after Taxotere use.
If you or a loved one used Taxotere and subsequently developed vision problems, contact TorHoerman Law to discuss your legal options today, including the possibility of filing a Taxotere Lawsuit.
The Taxotere litigation is ongoing, and Taxotere Lawsuits are being consolidated into multidistrict litigation (MDL).
Multidistrict litigation (MDL) is a special federal legal procedure designed to speed up the process of products liability litigation and ensure consistent decisions across all vision damage lawsuits.
Currently, there is not a Taxotere class action lawsuit.
Rather, Taxotere Lawsuits are consolidated into multidistrict litigation.
Multidistrict litigation is a special federal legal procedure used to consolidate cases of similar fact into one singular district court.
Multidistrict litigation and class action lawsuits are different from each other.
In multidistrict litigation, settlements are distributed to plaintiffs according to the damages and circumstances of each individual case.
In class action lawsuits, settlement compensation would be divided evenly among plaintiffs, regardless of the individual circumstances of each person.
Law firms often use “Taxotere Class Action Lawsuit”, “Taxotere Class Action MDL”, and other terms to describe the multidistrict litigation, but these terms are incorrect.
Bellwether trials are an important step in multidistrict litigation.
As multidistrict litigation consolidates cases of similar fact into one district court, some MDL plaintiffs are selected to participate in bellwether trials.
A bellwether trial is a small consolidation of lawsuits, taken from a larger group of similar cases, to be tried first.
The bellwether trial is like a practice run to help anticipate the results of future similar cases.
Temporary hair loss is a common side effect of most chemotherapy treatments.
However, most do not cause a complete loss of hair.
Studies find that among all of the side effects associated with chemotherapy, temporary hair loss has the greatest impact on a patient’s quality of life.
Taxotere has been linked to Alopecia, permanent hair loss, in those who take the drug for chemotherapeutic treatment.
Alopecia is a permanent and irreversible hair loss disease that affects all body hair, including:
Eyebrows
Eyelashes
Facial hair
Pubic hair
Multiple studies have found that Taxotere use can result in Alopecia.
Evidence of Alopecia occurring in Taxotere patients includes:
Documents from the Sanofi-funded GEICAM 9805 study – which was presented as evidence in ongoing litigation against Sanofi, that reveal that around 9.2% of patients suffered hair loss that lasted more than a decade.
A 2006 study conducted by the Rock Mountain Cancer Centers, which found that Taxotere caused 6% of women to suffer permanent alopecia.
A 2012 study published in the Annals of Oncology. Of the 20 female participants who received Taxotere, 19 developed permanent hair loss. One participant who was being treated for reoccurring breast cancer had previously undergone chemotherapy with a different drug and had complete hair regrowth, but after using Taxotere, she suffered from permanent hair loss.
Alopecia can severely affect a person’s quality of life, affect body image, and cause depression and distress.
For women who already have to struggle with the burden of breast cancer and chemotherapy, developing Alopecia can be devastating.
For breast cancer survivors, Alopecia is more than a cosmetic effect.
The disease is a constant reminder of the struggle to fight breast cancer.
The 2012 study published in the Annals of Oncology found that women who suffered from Alopecia due to Taxotere suffered “significant impairment” to their quality of life.
Patients who were prescribed Taxotere during chemotherapy allege that the manufacturer failed to adequately warn about permanent side effects linked to the drug.
While Taxotere treatment is designed to stop the spread of cancer cells, many individuals undergoing treatment reported permanent hair loss, chronic tearing, and other long-term complications that were not fully disclosed.
Clinical studies, including research from Rocky Mountain Cancer Centers, found higher rates of permanent alopecia in Taxotere patients compared to those who received other chemotherapy drugs.
The lawsuits argue that the drug’s safety profile was misrepresented, leaving patients and physicians without the full picture of potential risks when making treatment decisions.
Beyond the physical and emotional toll, these side effects contribute to significant medical costs, additional procedures, and ongoing quality-of-life challenges.
By filing suit, affected patients seek compensation for these damages and accountability from the drug’s manufacturer.
Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
Legally Reviewed
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
Fact-Checked
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
Additional Taxotere Lawsuit resources on our website:
150 Taxotere Lawsuits relating to vision loss and eye injuries are centralized in federal court.
Our Taxotere Lawyers are accepting new clients who have suffered vision loss, blurred vision, significant pain, and other visions issues after being prescribed Taxotere.
Contact us today for a free consultation or use the chat feature on this page to find out if you qualify for the Taxotere Lawsuit.
TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.
